The Swedish Radiosurgery Center is the lead site in a national multi-institutional study evaluating CyberKnife for treating men with intermediate-risk prostate cancer (clinical stage 2). As the principal investigator of this study, I reported on the quality of life outcomes at the annual meeting of American Society of Radiation Oncology.
We now know that in low-risk prostate cancer patients (stage 1), active surveillance is a safe option. But men with intermediate-risk cancer have a significant risk of dying of their disease, so intervention is necessary. Conventional treatments (surgery, radioactive seed implants and external beam radiotherapy) can adversely affect patients’ quality of life. We sought to determine if the unprecedented accuracy of CyberKnife treatment would translate into improvement in these patients’ quality of life.
We treated ..